LADENBURG THALM/SH SH Has Lowered Expectations for electroCore (NASDAQ:ECOR) Stock Price

electroCore (NASDAQ:ECOR) had its price objective dropped by LADENBURG THALM/SH SH from $28.00 to $26.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s target price would indicate a potential upside of 172.25% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of electroCore in a report on Thursday.

electroCore Trading Down 26.5 %

ECOR stock traded down $3.45 during trading hours on Thursday, hitting $9.55. 814,351 shares of the stock were exchanged, compared to its average volume of 63,513. The firm has a market capitalization of $63.56 million, a P/E ratio of -5.22 and a beta of 0.24. electroCore has a 12 month low of $5.32 and a 12 month high of $19.49. The company has a 50-day simple moving average of $16.16 and a two-hundred day simple moving average of $12.26.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ECOR. Renaissance Technologies LLC increased its stake in shares of electroCore by 80.6% in the fourth quarter. Renaissance Technologies LLC now owns 131,786 shares of the company’s stock valued at $2,136,000 after buying an additional 58,800 shares during the period. HighTower Advisors LLC bought a new position in electroCore in the third quarter worth approximately $255,000. Marshall Wace LLP bought a new position in shares of electroCore in the 4th quarter worth $438,000. Jane Street Group LLC acquired a new position in shares of electroCore during the fourth quarter valued at about $278,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of electroCore in the fourth quarter worth approximately $274,000. Institutional investors own 26.74% of the company’s stock.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.